- Home
- / CureVac
CureVac
Stock Price
$2.9
2024-10-29
Market Capitalization
$648.3 M
2024-10-29
Revenue
€535.2 M
FY, 2024
CureVac Summary
Company Summary
- Overview
- CureVac is a biotechnology company offering messenger RNA (mRNA) technology. It develops mRNA-based prophylactic vaccines addressing infectious diseases, RNA-based cancer immunotherapies, and molecular therapies.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Tübingen, DE | view all locations
- Website
- https://www.curevac.com/en/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Pierre Kemula, Chief Financial Officer
Malte Greune, Chief Operating Officer
Sarah Fakih, Vice President Corporate Communications & Investor Relations
Operating MetricsView all
Patent Applications
500
Mar, 2020
Pre-Clinical Discovery Phase Products
17
183.3%
Jun, 2023
Pre-Clinical Development Phase Products
7
Jun, 2023
LocationsView all
6 locations detected
Tübingen, BW HQ
Germany
Friedrich-Miescher-Straße 15
Boston, MA
United States
250 Summer St 3rd Fl
Ottignies-Louvain-la-Neuve, Région Wallonne
Belgium
Av. Jean Monnet 4
Wiesbaden, HE
Germany
Leipziger Str. 35
Amsterdam, NH
Netherlands
Science Park 106
Basel, BS
Switzerland
Wartenbergstrasse 40
CureVac Financials
Summary Financials
- Revenue (Q1, 2025)
- €893.0K
- Gross profit (Q1, 2025)
- (€991.0K)
- Net income (Q1, 2025)
- (€52.1M)
- Cash (Q1, 2025)
- €438.3M
- EBIT (Q1, 2025)
- (€54.7M)